Speed dominates modern business culture. Companies race to market with new products, prioritize rapid iteration over thorough development, and measure success in quarterly increments. The beauty industry exemplifies this velocity, with brands launching seasonal collections and limited-edition products at breakneck pace. Within this environment, Neora’s deliberate approach to product development stands out as an anomaly—one that challenges assumptions about innovation and effectiveness.
The company’s “go slow to go fast” philosophy might seem counterintuitive in a market that rewards first movers and novelty. However, this patient methodology addresses fundamental issues that plague rush-to-market approaches. When development timelines compress, formulations get approved once they meet minimum standards rather than being optimized for maximum efficacy. Testing periods shorten, potentially missing long-term effects or uncommon reactions. Ingredient selection prioritizes availability and cost over ideal performance characteristics.
Amber Olson Rourke articulates the company’s perspective: “We take our time with products, we take our time with the development, and that’s why we don’t have 50 products in our 12 years.” This statement acknowledges a trade-off: fewer products but better ones. The patience required for this approach demands confidence that quality will ultimately drive success more reliably than quantity.
The development story of SIG-1273 provides concrete illustration of what patient development means in practice. The product required 1,273 iterations to achieve its final formulation—a number that seems almost absurd compared to typical cosmetic development timelines. Each iteration involved formulation, stability testing, preliminary efficacy assessment, and analysis of results. Problems identified led to adjustments. Promising directions received further refinement. The process continued until the team achieved a formulation that met all criteria for safety, stability, and performance.
This iterative process allows for optimization that rushed development cannot achieve. Early formulations might work adequately, delivering measurable benefits in testing. A company focused on speed would approve such formulations and proceed to manufacturing. However, “adequate” differs substantially from “optimal.” The additional iterations that take a good formulation and make it excellent require time that many companies won’t invest. Neora’s willingness to continue refining reflects commitment to creating truly superior products rather than merely acceptable ones.
The patience extends beyond formulation into ingredient selection. The choice of marine collagen over bovine collagen exemplifies this approach. Marine collagen costs more, requires more complex sourcing, and comes with additional regulatory considerations. A time-pressured development process might default to bovine collagen simply for convenience. The slower pace allows for thorough evaluation of ingredient options, considering not just immediate factors like cost and availability but also long-term considerations like sustainability, efficacy, and alignment with brand values.
Clinical testing represents another area where patient development delivers advantages. Comprehensive testing takes time—months or years to conduct studies that evaluate both short-term and long-term effects. Participants must use products consistently over extended periods to assess sustained benefits and identify any delayed reactions. Proper statistical analysis requires sufficient sample sizes and appropriate controls. Rushing this process might produce positive results that don’t withstand scrutiny or miss important effects that only become apparent with extended use.
Third-party clinical testing adds another layer of time to the development process but provides crucial validation. Internal testing might face questions about objectivity, regardless of how rigorously conducted. Independent laboratories eliminate this concern by providing unbiased assessment. Coordinating with external facilities, submitting materials, and waiting for results extends timelines significantly compared to relying solely on internal evaluation. Companies focused on speed often skip this step, missing the credibility benefits that independent verification provides.
The emphasis on multibenefit formulations rather than single-purpose products also reflects patient development philosophy. Creating a product that effectively addresses multiple skin concerns simultaneously requires more sophisticated formulation than targeting a single issue. Ingredients must complement rather than interfere with each other. Concentrations need careful balancing to ensure each component delivers benefits without overwhelming the formulation. Testing must verify that all intended effects occur together rather than canceling each other out. This complexity demands time that single-purpose product development doesn’t require.
Market education presents another dimension where patient development proves advantageous. When a company launches numerous products rapidly, customer education becomes superficial by necessity—there’s simply too much to explain in depth. A smaller product line developed over years allows for comprehensive education about each item. Customers can learn not just what products do but how they work, why specific ingredients were chosen, and what realistic expectations they should have. This depth of education builds understanding that enhances product effectiveness by ensuring proper use.
The slow development approach also allows for better alignment with emerging research. Skincare science continues evolving, with new discoveries about skin biology, ingredient interactions, and optimal delivery systems appearing regularly. A lengthy development process creates opportunities to incorporate these advances as they emerge. Formulations locked in quickly based on knowledge from years earlier might miss important insights that become available during extended development periods.
Consumer trends also benefit from patient observation rather than hasty response. The beauty industry frequently experiences ingredient fads where components gain popularity based more on marketing than science. Companies rushing to capitalize on these trends sometimes formulate products around ingredients that prove less effective than initial hype suggested. Waiting to observe how trends play out allows for more informed decisions about which innovations warrant incorporation and which represent passing fancies.
The financial implications of slow development deserve consideration. Extended development cycles mean longer periods before products generate revenue. Testing costs accumulate over time. The capital tied up in development projects can’t be deployed elsewhere. These factors create pressure to accelerate timelines and launch products before fully optimized. Resisting this pressure requires conviction that superior products will ultimately deliver better returns than faster products.